[Clinical study of sultamicillin fine granules]
Related Experiment Videos
K Okada1, K Kawakami, E Takeda
1Department of Pediatrics, School of Medicine, Tokushima University.
Insights
Sultamicillin, a combined antibiotic and beta-lactamase inhibitor prodrug, showed an 83.3% efficacy rate in treating pediatric infectious diseases. The treatment was well-tolerated, with minimal side effects observed in the study group.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Sultamicillin is a mutual prodrug combining ampicillin and sulbactam.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose:
- To evaluate the clinical efficacy and safety of sultamicillin in pediatric patients with infectious diseases.
Summary:
- Nineteen children (9 boys, 10 girls; aged 11 months to 13 years) received oral sultamicillin (15.4-40.8 mg/kg/day) for 3-12 days.
- Clinical efficacy was rated as excellent in 2, good in 13, and fair in 3 cases, yielding a total efficacy rate of 83.3%.
- Side effects included loose stool in one patient and mild diarrhea in another; no abnormal laboratory values were noted.
Impact:
- Sultamicillin demonstrates significant clinical efficacy in treating pediatric infectious diseases.
- The drug exhibits a favorable safety profile in the pediatric population.
- These findings support the use of sultamicillin as a therapeutic option for children with bacterial infections.
Abstract:
Sultamicillin, a mutual prodrug of a beta-lactam antibiotic and beta-lactamase inhibitor, was administered to 19 child patients with infectious diseases. The patients included 9 boys and 10 girls from 11 months to 13 years old and they were given orally a dosage of 15.4-40.8 mg/kg/day for 3 to 12 days. Clinical efficacies were excellent in 2 cases, good in 13 cases, fair in 3 cases, unknown in 1 case, and the total efficacy rate was 83.3%. Loose stool in 1 case and mild diarrhea in another occurred as side effects of the drug, but no abnormal laboratory test values were found upon the treatment.